Adagio Medical Q3 2024 revenue $185K (+351% YoY); net loss $4.6M; CMS coverage secured

Adagio Medical Holdings, Inc.

2024-Q3 EPS reported $0.02 revenue$132,000

Revenue of $185K in Q3 2024, up 351% from $41K in Q3 2023.
Net loss of $4.6M improved from $10.8M in Q3 2023; driven by fair value changes on convertible notes.
Cash and short-term investments of $28.3M as of September 30, 2024.
CMS Category B coverage secured for vCLAS catheter in FULCRUM-VT IDE study for drug-resistant VT.
First procedures performed in FULCRUM-VT pivotal study; 206 patients at 20 US/Canadian centers to support FDA PMA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.